We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment

By LabMedica International staff writers
Posted on 12 Mar 2025
Print article
Image: Among the proteins in the cerebrospinal fluid, the researchers identified biomarkers that can accurately predict the development of ICANS (Photo courtesy of Daiki Setoyama/Kyushu University)
Image: Among the proteins in the cerebrospinal fluid, the researchers identified biomarkers that can accurately predict the development of ICANS (Photo courtesy of Daiki Setoyama/Kyushu University)

In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves genetic modifications to a patient's T cells to enable them to target and destroy cancer cells. While this treatment has shown success, particularly in blood cancers, it is not without its risks. One of the severe side effects associated with CAR-T therapy is immune effector cell-associated neurotoxicity syndrome (ICANS), which causes inflammation in the central nervous system. Symptoms of ICANS range from mild issues like headaches and lethargy to more severe manifestations such as impaired consciousness, seizures, or even brain hemorrhages. The incidence of ICANS after CAR-T therapy is high, estimated at around 64%, but there has been no reliable method to predict its severity until now. Researchers have now discovered a method to predict this life-threatening side effect before it occurs.

Researchers at Kyushu University (Fukuoka, Japan) analyzed cerebrospinal fluid collected before treatment to identify proteins linked to harmful immune responses that affect the central nervous system following therapy. Published in Leukemia, the study could make cancer immunotherapy safer by helping doctors identify high-risk patients ahead of time, allowing them to implement early interventions or even prevent the condition. In this study, the team analyzed cerebrospinal fluid samples from 29 patients with B-cell non-Hodgkin's lymphoma before they underwent CAR-T therapy. Out of the cohort, 11 patients developed ICANS, while 18 did not.

The team identified 864 proteins across all spinal fluid samples, narrowing down the list to 46 proteins that displayed significant differences in concentration between patients who developed ICANS and those who did not. These proteins became potential biomarkers for predicting ICANS. The researchers pinpointed two key proteins: C1RL, which was elevated in patients who developed ICANS, and FUCA2, which had lower levels in those patients. When combined, the ratio of these two proteins proved to be highly accurate in distinguishing patients at high risk of developing ICANS from those at low risk. To validate their findings, the team tested the C1RL/FUCA2 biomarker on a second group of 10 patients undergoing CAR-T therapy, and in all cases, the protein ratio correctly predicted the risk of developing ICANS. However, the researchers noted that the small sample size means the results are preliminary and need further validation.

Beyond aiding in early detection and timely treatment, the researchers hope their identification of these biomarkers will allow for preventive measures before CAR-T therapy begins. For instance, since C1RL is involved in the complement system, which is known to trigger inflammation and may contribute to ICANS, patients identified as high-risk could be preemptively treated with drugs that inhibit this system. This predictive test could lead to a more personalized and safer approach to cancer treatment. Additionally, the research team plans to expand their investigation to see if these biomarkers can be applied to other blood cancers beyond B-cell non-Hodgkin's lymphoma. They are also exploring the potential for using easier-to-collect fluids, such as blood serum, to find more accessible biomarkers for treatment monitoring.

“Spinal fluid collection is an invasive and painful procedure, so most hospitals in Japan and other countries don’t routinely perform it before CAR-T therapy,” said Dr. Tomoko Nomiyama, co-first author and clinical technologist at Kyushu University Hospital. “If we can identify similar biomarkers in blood, our test would become a much simpler and more accessible tool for predicting ICANS.”

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.